Scroll down to view all MGFA poster titles and onsite numbers that were submitted and accepted. MG numbers represent actual poster locations at the AANEM conference and Muscle & Nerve numbers are specifically listed in the AANEM published supplement.
MGFA Scientific Session Poster Titles and location numbers
| MG Poster Location Number | Muscle&Nerve# | First Name | Last Name | Suffix | Poster Title |
| MG 1 | 106 | Samreen | Ahmed | MBBS | A Text Messaging-Based Patient Education Program Aimed At Improving Outcomes In Myasthenia Gravis. |
| MG 2 | 40 | Maria | Ait-Tihyaty | PhD | Disease Burden In Patients With Generalized Myasthenia Gravis |
| MG 3 | 78 | Maria | Ait-Tihyaty | PhD | Partnering With Patients And Caregivers To Guide The Development Of Impactful Study Engagement Tools In A Generalized Myasthenia Gravis Real World Study |
| MG 4 | 97 | Maria | Ait-Tihyaty | Ph.D | Nipocalimab, A New Neonatal Fragment Crystallizable Blocker, Leads To Rapid, Substantial And Sustained Generalized Myasthenia Gravis Disease Control |
| MG 5 | 13 | Mayra | Aldecoa | Fellowship | Transcriptome-Wide And Stratified Genomic Structural Equation Modeling Identify Neurobiological Pathways Shared Across Myasthenia Gravis And Neuropsychiatric Disorders |
| MG 6 | 105 | Priyanshu | Bansal | MD | Review Of Efficacy Of New Complement Inhibiting Monoclonal Antibodies In Myasthenia Gravis: A Real World Experience From A Tertiary Neurology Center. |
| MG 7 | 54 | Taylor | Bauman | BS | Is Residual Serum Fibrinogen A Biomarker For Myasthenia Gravis? |
| MG 8 | 65 | Sara | Benitez | MD | Treatment Related Infection In Myasthenia Gravis |
| MG 9 | 56 | Ratna | Bhavaraju-Sanka | MD | Patterns Of Efgartigimod Dosing In Clinical Practice In The United States |
| MG 10 | 83 | Alexandra | Bonner | MD | Determination Of The Optimal Compound Muscle Action Potential Amplitude Decrement Cutoff Values In The Diagnosis Of Myasthenia Gravis Using Repetitive Nerve Stimulation Studies |
| MG 11 | 60 | Martin | Brandhoj Skov | Ph.D. | Unmet Needs In Myasthenia Gravis: Patient And Physician Perspectives |
| MG 12 | 4 | Jiaxin | Chen | MD, PhD | Therapeutic Plasma Exchange In Achr-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response |
| MG 13 | 21 | Jiaxin | Chen | MD, PhD | Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review And Meta-Analysis |
| MG 14 | 31 | Pei | Chen | MD, PhD | Extraocular Muscle Volume On Time-Of-Flight Magnetic Resonance Angiography In Patients With Myasthenia Gravis |
| MG 15 | 32 | Pei | Chen | MD, PhD | Conventional Dendritic Cells Are More Activated In The Hyperplastic Thymus Of Myasthenia Gravis Patients |
| MG 16 | 67 | Zia | Choudhry | MD, PhD, MBA | Leveraging Ai To Characterize Mental Health Experiences Throughout The Myasthenia Gravis Diagnosis Journey |
| MG 17 | 68 | Zia | Choudhry | MD, PhD, MBA | Uncontrolled Myasthenia Gravis Can Contribute To Additional Stress Burden And Adverse Mental Health Experiences |
| MG 18 | 69 | Zia | Choudhry | MD, PhD, MBA | Sentiment Analysis Of Digital Conversations Related To Myasthenia Gravis By Race/Ethnicity |
| MG 19 | 33 | Marta | Cossu | MD, PhD | A Randomized, Open-Label Study On The Effect Of Nipocalimab On Vaccine Responses In Healthy Participants |
| MG 20 | 92 | Dubravka | Dodig | MD, BSc, FRCPC | Dismantling Of Neuromuscular Junction In Myasthenia Gravis – A Point Of No Return |
| MG 21 | 110 | Eleni | Drakou | MD | Identifying Healthcare Disparities In Myasthenia Gravis: A Post-Covid-19 Pandemic Bronx Tale |
| MG 22 | 36 | Rebecca | Dutta | MD | Recessive Syt2-Congenital Myasthenic Syndrome Caused By A Maternal Uniparental Disomy Of Chromosome 1 |
| MG 23 | 11 | Christopher | Evans | MD (Candidate) | A Study Of The Common Factors That Influence Fatigue In Myasthenia Gravis |
| MG 24 | 64 | Constantine | Farmakidis | MD | Long-Term Safety And Efficacy Of Nipocalimab In Generalized Myasthenia Gravis: Vivacity-Mg3 Open-Label Interim Analysis |
| MG 25 | 103 | Constantine | Farmakidis | MD | Symptom Severity Assessment Using Mg-Adl Items And Domains In A 24-Week, Phase 3 Study (Vivacity) Of Nipocalimab In Generalized Myasthenia Gravis. |
| MG 26 | 24 | Alexander | Fay | MD, PhD | Seronegative Myasthenia Gravis In Children With Autoinflammatory Syndromes |
| MG 27 | 52 | Miriam | Freimer | MD | Switching To Subcutaneous Zilucoplan From Iv Complement Component 5 Inhibitors In Myasthenia Gravis: A Phase 3B Study |
| MG 28 | 61 | Miriam | Freimer | MD | Corticosteroid Dose Tapering During Treatment With Zilucoplan In Patients With Generalized Myasthenia Gravis: 120-Week Follow-Up Of Raise-Xt |
| MG 29 | 57 | Rachana K. | Gandhi Mehta | MD | Self-Administration Of Subcutaneous Rozanolixizumab In Patients With Generalized Myasthenia Gravis: Clinical Study Design |
| MG 30 | 1 | Mariam | Gigilashvili | M.D. | Unique Case Of Post-Covid19 Myasthenia Gravis With Spontaneous Resolution |
| MG 31 | 63 | Cynthia | Qi | Dir | Real-World Reduction In Oral Corticosteroid Utilization At 1-Year Following Efgartigimod Initiation |
| MG 32 | 95 | Jeffrey | Guptill | MD | Dose Selection And Clinical Development Of Efgartigimod Ph20 Subcutaneous In Patients With Generalized Myasthenia Gravis |
| MG 33 | 22 | Kelly | Gwathmey | MD | Cyclic And Every-Other-Week Dosing Of Intravenous Efgartigimod For Generalized Myasthenia Gravis: Part A Of Adapt Nxt |
| MG 34 | 98 | Kelly G. | Gwathmey | MD | Evaluation Of The Indirect And Nonmedical Impacts Of Generalized Myasthenia Gravis On Patients And Caregivers |
| MG 35 | 81 | Ali A. | Habib | MD | Rozanolixizumab Treatment Patterns In Patients With Generalized Myasthenia Gravis: Post Hoc Analysis |
| MG 36 | 48 | Aiden | Haghikia | MD | Design Of Kysa-6, A Phase 2, Open-Label, Multicenter Study Of Kyv-101, A Novel Fully Human Anti-Cd19 Chimeric Antigen Receptor T-Cell Therapy In Refractory Generalized Myasthenia Gravis |
| MG 37 | 9 | Lauren | Herrera | MD | Mismatch Between Neuromuscular Specialists And Myasthenia Gravis Patients In The Us Medicare Population |
| MG 38 | 102 | James | Howard | MD | Design Of A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Subcutaneous Efgartigimod Ph20 Administered By Prefilled Syringe In Adults With Ocular Mg |
| MG 39 | 37 | James F. | Howard Jr | MD | Phase 3 Trial Investigating Impact Of Intravenous Efgartigimod In Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis |
| MG 40 | 74 | James F. | Howard Jr. | MD | Long-Term Safety And Efficacy Of Zilucoplan In Generalized Myasthenia Gravis: 120-Week Interim Analysis Of Raise-Xt |
| MG 41 | 75 | James F. | Howard Jr. | MD | Developing Needs-Driven Medical Education For Healthcare Professionals In Myasthenia Gravis |
| MG 42 | 99 | James F. | Howard Jr. | MD, FAAN | The Phase 3 Prevail Study Assessing The Efficacy And Safety Of Subcutaneous Gefurulimab In Adults With Generalized Myasthenia Gravis: Trial In Progress |
| MG 43 | 14 | James F. | Howard, Jr. | MD | Development Of A Myasthenia Gravis Patient Journey Map As A Tool To Identify Challenges And Unmet Needs In The Patient Community |
| MG 44 | 107 | Sazan | Ismael | PhD | Developing Musk L-Cba To Detect Anti-Musk Antibody |
| MG 45 | 70 | Louis | Jackson | PharmD | Factors Influencing Exacerbations And Crises In Generalized Myasthenia Gravis: Findings From A Claims Database Study |
| MG 46 | 71 | Louis | Jackson | PharmD | Impact Of Race And Social Determinants Of Health On Exacerbations In Generalized Myasthenia Gravis |
| MG 47 | 20 | Henry | Kaminski | MD | Quantitating Factors Influencing The Myasthenia Gravis Telehealth Examination |
| MG 48 | 87 | Henry | Kaminski | MD | Oral Cladribine Capsules For Generalized Myasthenia Gravis: Design Of An Actively-Recruiting Phase 3 Clinical Study – The Myclad Study |
| MG 49 | 73 | Hans | Katzberg | MD | Safety And Efficacy Of Subcutaneous Immunoglobulin In Patients With Generalized Myasthenia Gravis |
| MG 50 | 34 | Anosha | Khan | N/A | Towards A Genome-Wide Association For Musk Myasthenia Gravis |
| MG 51 | 89 | Fatemeh | Khani-Habibabadi | PhD | Distribution And Temporal Changes Of Autoantibody-Mediated Pathogenic Mechanisms Among Achr-Positive Mg Patients |
| MG 52 | 39 | Vera | Kiyasova | MD, PhD | Nmd670, A First-In-Class Skeletal Muscle Clc-1 Inhibitor In Myasthenia Gravis: The Synapse-Mg Dose-Finding Study |
| MG 53 | 84 | Vera | Kiyasova | MD, PhD | Clc-1 Inhibition Improves Qmg Score And Skeletal Muscle Function In Patients With Myasthenia Gravis |
| MG 54 | 108 | Tyler | Krall | BS | Clinical Outcomes Of Adult Myasthenia Gravis Patients On Efgartigimod: A Retrospective Chart Review |
| MG 55 | 23 | Yuebing | Li | MD, PhD | Epidemiological Study Of Myasthenia Gravis In Elderly Us Population: A Longitudinal Analysis Of The Medicare Claims Database From 2006-2019 |
| MG 56 | 49 | Huining | Li | Doctorate | Treatment Strategy Towards Myasthenia Gravis With Gad65-Igg Associated Neurological Disorders |
| MG 57 | 88 | Yingkai (Kevin) | Li | MD | Imbalanced Pro-Inflammatory Immune Responses In Seropositive And Seronegative Mg |
| MG 58 | 100 | Cathy Meng Fei | Li | MD | Mediastinal Radiotherapy For Non-Operable Thymoma With Myasthenia Gravis |
| MG 59 | 94 | Alexis | Lizarraga | MD | Comorbidities In Seropositive And Seronegative Myasthenia Gravis: A Single Center Experience |
| MG 60 | 15 | Ching | Lum | PharmD | Pozelimab And Cemdisiran Combination Therapy In Patients With Myasthenia Gravis: Phase 3 Nimble Trial Design |
| MG 61 | 7 | Sushan | Luo | MD,PhD | Clinical Outcome In Impending Myasthenic Crisis: A Prospective Cohort Study |
| MG 62 | 112 | Lindsay | Malatesta | MD | Alternative Dosing Of Efgartigimod In Myasthenia Gravis |
| MG 63 | 8 | Julia | Manasson | MD | Preclinical Pharmacology Of S-1117, A Novel Engineered Fc-Fused Igg Cleaving Enzyme, For Chronic Treatment Of Autoantibody-Mediated Diseases Including Myasthenia Gravis |
| MG 64 | 58 | Alexandra | McMillan | BS, MS, MD | Simultaneous Myasthenia Gravis-Polymyositis Overlap Syndrome, A Case Report |
| MG 65 | 18 | Lesley-Ann | Miller-Wilson | PhD, MS, MBA | Characteristics And Treatment Patterns Of A United States Generalized Myasthenia Gravis Population: Interim Analysis Of Real-World Data |
| MG 66 | 28 | Lesley-Ann | Miller-Wilson | PhD, MS, MBA | Evidence Gap Analysis Of The Burden Of Disease And Treatment Of Myasthenia Gravis |
| MG 67 | 46 | Ali | Mousavi | MD | Enhanced Laboratory Detection Of Anti-Acetylcholine Receptor Antibody Contributes To Rising Incidence Myasthenia Gravis |
| MG 68 | 93 | Srikanth | Muppidi | MD | Observed Efficacy Of Efgartigimod In Generalized Myasthenia Gravis Across Patient Subgroups In The Adapt-Sc+ Study |
| MG 69 | 5 | Lauren | Nguyen | M.Sc. | One Patient With Three Antibody- Confirmed Neurological Autoimmune Syndromes: A Case Report |
| MG 70 | 41 | Richard | Nowak | MD, MS | Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study Of Inebilizumab In Patients With Generalized Myasthenia Gravis (Mint): Topline Efficacy And Safety Findings |
| MG 71 | 44 | Richard | Nowak | MD, MS | The Myasthenia Gravis Patient Registry: Characteristics, Insights, And Learnings After A Decade (2013-23) |
| MG 72 | 86 | Richard J. | Nowak | MD, MS | Change In Concomitant Immunosuppressive Therapies For Generalized Myasthenia Gravis In Patients Receiving Complement C5 Inhibitor Therapies: A Retrospective Analysis Of Registry Data |
| MG 73 | 109 | Richard | Nowak | MD, MS | Exploring Outcomes And Characteristics Of Myasthenia Gravis 2 (Explore-Mg2): Design, Rationale, And Baseline Results |
| MG 74 | 111 | Ananda | Pandurangadu | MD | Expediting Myasthenia Gravis Diagnostic Evaluation: A Novel, Proof-Of-Concept Tool For Undiagnosed, Symptomatic Patients That Uses Social Media Targeting And Self-Assessment |
| MG 75 | 55 | Shirali | Pandya | MPH, PhD | Incidence And Outcome Of Meningococcal Infection With Eculizumab Or Ravulizumab In Patients With Gmg Or Nmosd: An Analysis Of Us Clinical Practice |
| MG 76 | 51 | Robert M. | Pascuzzi | MD | Effect Of Rozanolixizumab On Myasthenia Gravis–Specific Outcome Subdomain Scores: Post Hoc Analyses From The Phase 3 Mycaring Study |
| MG 77 | 114 | Mamatha | Pasnoor | MD | Safety And Tolerability Of Whole-Body Electrical Muscle Stimulation Exercise In Adults With Myasthenia Gravis: A Preliminary Analysis |
| MG 78 | 3 | Sheryl | Pease | MBA | Assessing The Suitability Of The Neuro-Qol Fatigue To Evaluate Fatigue In Patients Living With Myasthenia Gravis |
| MG 79 | 104 | Tefani | Perera | MD | Feasibility Of 12 Weeks Of Remote Monitoring In Generalized Myasthenia Gravis |
| MG 80 | 12 | Prashanth | Poulose | DM Neurology | Imaging Patterns In Congenital Myasthenic Syndrome (Cms) – Insights From Mri |
| MG 81 | 26 | Anna | Punga | MD, PhD | Visualization And Characterization Of Complement Activation In Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis |
| MG 82 | 29 | Anna | Punga | MD, PhD | Short-Term Changes In Serum Mirna Levels And Patient-Reported Outcomes In Myasthenia Gravis |
| MG 83 | 45 | Anna | Punga | MD, PhD | Elevated C1S/C1-Inh In Serum And Plasma Of Myasthenia Gravis Patients |
| MG 84 | 47 | Anna | Punga | MD, PhD | A Serum Inflammatory Protein Biomarker Profile Defines Acetylcholine Receptor Antibody Seropositive Myasthenia Gravis |
| MG 85 | 17 | Manvi | Punukollu | BS | Comparative Efficacy Of Treatment Modalities In Myasthenia Gravis |
| MG 86 | 59 | Cynthia | Qi | N/A | Exploring The Impact Of Nonsteroidal Immunosuppressive Drugs And Steroids On The Development Of Comorbidities In Patients With Myasthenia Gravis In The National Veterans Affairs Health Network |
| MG 87 | 80 | Cynthia | Qi | MBA | Quality Of Life Of Ocular Mg Patients With Persistent Symptoms: Comparison With The General Population |
| MG 88 | 25 | Chuan | Qin | MD, PhD | Anti-Bcma Car T-Cell Therapy In Patients With Refractory Myasthenia Gravis |
| MG 89 | 35 | Vijayaraghava | Rao | PhD | Steroid Use, Toxicity, And Monitoring In Patients With Generalized Myasthenia Gravis: A Survey Of Neurologists In The United States |
| MG 90 | 90 | Bhaskar | Roy | MBBS | Proteomic Analysis Reveals A Distinct Immunological Signature For Late-Onset Myasthenia Gravis |
| MG 91 | 101 | Chloe | Sader | PharmD | Safety Outcomes In Pregnant Patients Treated With The Complement 5 Inhibitor Therapy (C5It) Eculizumab |
| MG 92 | 85 | Christopher A. | Scheiner | MD, PhD | Outcomes For Patients With Generalized Myasthenia Gravis Prescribed Ravulizumab, Eculizumab, Or Efgartigimod Treatment: Interim Analysis Of A Retrospective Medical Record Analysis (Elevate) |
| MG 93 | 76 | John | Sheehan | PhD | Perinatal Treatment Patterns In Myasthenia Gravis |
| MG 94 | 77 | John | Sheehan | PhD | Adverse Pregnancy Outcomes In Myasthenia Gravis: A Retrospective Cohort Study In A Us Health Insurance Claims Database |
| MG 95 | 96 | Patricia | Sikorsi | PhD | Alterations In Peripheral B And T Cell Subsets In Musk-Mg Subjects After Rituximab Treatment |
| MG 96 | 19 | Nicholas | Silvestri | MD | Real-World Experience With Individualized Dosing Of Efgartigimod In Patients With Generalized Myasthenia Gravis |
| MG 97 | 82 | Martin | Skov | PhD | Clc-1 Inhibition Improves Skeletal Muscle Function In Rat Models And Patients With Myasthenia Gravis. |
| MG 98 | 72 | A. Gordon | Smith | MD | Comparative Risk-Benefit Profiles Of Immunomodulatory Therapies For Patients With Generalized Myasthenia Gravis |
| MG 99 | 2 | Hunter | Soleymani | MD | Clinical Eyelid Myotonia In Myasthenia Gravis |
| MG 100 | 66 | Jonathan | Strober | MD | Safety And Effectiveness Of Nipocalimab In Adolescent Participants In The Open Label Phase 2/3 Vibrance-Mg Clinical Study |
| MG 101 | 16 | Ryan | Verity | MD | Efgartigimod Alfa-Fcab Use In A Pregnant Woman With Generalized Myasthenia Gravis: A Case Report |
| MG 102 | 43 | Tuan | Vu | MD | Efficacy And Safety Of Nipocalimab In Patients With Generalized Myasthenia Gravis: Topline Results From The Double-Blind, Placebo-Controlled, Randomized Phase 3 Vivacity-Mg3 Study |
| MG 103 | 53 | Tuan | Vu | MD | Rozanolixizumab In Patients Aged ≥65 Years With Generalized Myasthenia Gravis: A Post Hoc Analysis Of The Phase 3 Mycaring Study |
| MG 104 | 79 | Tuan | Vu | MD | Non-Steroidal Immunosuppressant Therapy Changes During Treatment With Zilucoplan In Patients With Generalized Myasthenia Gravis: 120-Week Follow-Up Of Raise-Xt |
| MG 105 | 91 | Tuan | Vu | MD | Safety And Efficacy Of Bcma-Directed Mrna Car T-Cell Therapy In Generalized Myasthenia Gravis |
| MG 106 | 27 | Haiyan | wang | Ph.D. | Fast-Acting Treatment Of Myasthenic Crisis With Efgartigimod From The Perspective Of The Neonatal Intensive Care Unit |
| MG 107 | 62 | Michael D. | Weiss | MD | Concomitant Intravenous Immunoglobulin Or Plasma Exchange Has No Effect On Complement Inhibition By Zilucoplan |
| MG 108 | 42 | Lauren | Williams | B.S. Biology | Clinical Experience With Rozanolixizumab For Treatment Of Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis |
| MG 109 | 38 | Ge | Xiong | MD, PhD | A Retrospective Case Series Of Myasthenia Gravis Associated With Immune Checkpoint Inhibitors |
| MG 110 | 50 | Jingwen | Yan | M.D. | The Mitochondrial Quality Control Mechanism Of Statins Affecting Myasthenia Gravis Patients With Hyperlipidemia |
| MG 111 | 30 | Sheng | Gao | PhD | Post-Hoc Analysis Of Clinically Relevant Anti-Vaccine Antibodies In Participants Treated With Nipocalimab |
| MG 112 | 113 | Li | Zhang | MD | Acetylcholine Receptor Antibodies As A Biomarker Of Treatment Strategy With Rituximab In Myasthenia Gravis |
| MG 113 | 6 | Huahua | Zhong | M.D. | Plasma Biomarker-Based Endotyping Reveals Distinct Inflammatory Patterns In Myasthenia Gravis Subtypes |
| MG 114 | 10 | Min | Zhu | M.D., Ph.D | Lambert-Eaton Myasthetic Syndrome May Not Be Coincidental In Prostate Cancer |